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In the presence ofGTP, GDP, GMPP(NH)P, GMPP(CHJP, GMPP(S)P but not in the presence of GMP, 
cGMP or ATP, the high affinity binding of neuropeptide Y (NPY) was reduced in a dose-dependent man- 
ner. GTP (0.1 mM) diminished the maximal binding capacity for *ZSI-labelled NPY by 40% without any 
change in the equilibrium dissociation constant of the receptor 1251-labelled NPY complex. 
Neuropeptide Y Neuropeptide Y-receptor GTP 
1. INTRODUCTION 2. MATERIALS AND METHODS 
Neuropeptide Y (NPY) [1,2] is a newly isolated 
36 amino acid residues long peptide which occurs 
in the brain in the highest amounts of all peptides 
hitherto reported. It is co-stored with nor- 
adrenaline in some peripheral neurons [3] and acts 
synergistically with it at several sites. Recently, a 
reversible and saturable high affinity binding of 
‘251-labelled NPY to membranes from rat cerebral 
cortex, hypothalamus, striatum and hippocampus 
has been reported [4,5]. We have here examined 
the effects of guanine nucleotides on the 
equilibrium binding of ‘*‘I-labelled NPY to recep- 
tors in membranes from the rat cerebral cortex. 
Natural purified porcine NPY was purified by 
Dr Kazuhiko Tatemoto as in [1] and iodinated by 
the chloramine-T method of Dr Elvar 
Theodorsson-Norheim and generously supplied to 
us. 
All chemicals used were of analytical grade. 
GTP Na+-salt was purchased from Sigma (St. 
Louis, MO). GMPP(NH)P, GMPP(CHz)P and 
GMPP(S)P were bought from Boehringer 
Mannheim. 
Guanine nucleotides have been shown to be in- 
volved in the hormone stimulation and inhibition 
of the adenylate cyclase in various tissues [6]. 
Guanine nucleotides lower the binding affinity of 
agonist in several systems including classical 
neurotransmitters such as norepinephine [7], 
acetylcholine [8] and peptides such as substance P 
[9], somatostatin [IO], and cholecystokinin [ 111. 
Activation or inhibition of adenylate cyclase by 
NPY has not yet been reported. However, guanine 
nucleotides affect the binding of ‘*‘I-labelled NPY 
causing a decrease in the number of binding sites 
with virtually no effect on binding affinity of 1251- 
labelled NPY. 
Adult male Sprague-Dawley rats weighing 
150-200 g were decapitated and the brains rapidly 
removed. Cerebral cortex was dissected, freed 
from white matter and homogenized in a loose fit- 
ting glass-teflon homogenizer in ice-cold sucrose 
(0.32 M) buffered with 5 mM Hepes (pH 7.4) to 
yield a 10% (w/v) homogenate. 
The homogenate was diluted lo-fold with 
Hepes-buffered (5 mM, pH 7.4) sucrose (0.32 M) 
before centrifugation at 1000 x g for 5 min. The 
resulting supernatant was subjected to further cen- 
trifugation at 10000 x g for 45 min. The obtained 
pellet was resuspended in Hepes-buffered (20 mM, 
pH 7.4) Krebs-Ringer buffer (137 mM NaCl, 2.68 
mM KCl, 2.05 mM MgCl2, 1.8 mM CaCl2 and 1 
g/l glucose) to yield a protein concentration of 
0.25 mg protein/ml. The protein concentration 
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was determined as in [12] using bovine serum 
albumin as standard. This crude mitochondrial 
membrane preparation is referred to as ‘mem- 
brane’ and was used without further fractionation. 
Equilibrium binding studies with 1251-labelled 
NPY were carried out in plastic centrifuge tubes by 
addition of 0.4 ml of ice-cold protein suspension in 
Krebs-Ringer buffer to 0.5 ml Hepes-buffered 
Krebs-Ringer buffer containing BSA (1 .O%, w/v) 
and various amounts of labelled NPY (1251-labelle.d 
NPY) and 100 1 of nucleotide solutions made up in 
BSA free Krebs-Ringer buffer. Nonspecific bind- 
ing was defined as the amount of ‘251-labelled NPY 
bound in the presence of unlabelled NPY (50 
pmol/sample). 
The incubations were carried out in a waterbath 
at 37°C for 45 min and were terminated by cen- 
trifugation for 1 min in a Beckman Microfuge (at 
10000 x g/min). The supernatant was aspirated 
off, the pellets were dried and the bottom of the 
plastic centrifuge tubes containing the pellets were 
cut off and placed into plastic tubes applicable to 
the Packard Autogamma 500 D counter equipped 
with a fixed window for 1251. The counting effi- 
ciency was 61.2%; 8% of the added 1251-labelled 
NPY was unspecifically bound to the upper part of 
the centrifuge which was discarded when the bot- 
tom containing the pellet was cut off. 
3. RESULTS AND DISCUSSION 
The equilibrium binding of 1251-labelled NPY 
OOAV 10 IL 
‘251-NPY ,nM I 
(O-l.5 nM) to receptors in membranes from rat 
cerebral cortex was decreased by 40% in the 
presence of GTP (0.1 mM, fig.lA). The Scatchard 
plot (fig.lB) clearly illustrates that there was no 
significant change in the Kd value of the binding of 
1251-labelled NPY. 
The B,,, values were 444 fmol/mg protein and 
265 fmol/mg protein in the absence and presence 
of GTP (0.1 mM) while the Kd values were 0.32 
and 0.28 nM, respectively. 
This effect of GTP was dose-dependent as 
shown in fig.2. The half maximal inhibition of 
binding of 1251-labelled NPY (0.2 nM) was caused 
by 10pM GTP. 
Other guanine triphosphate analogs such as 
GMPP(N)P gave a similar inhibition of 1251- 
labelled NPY binding (fig.2). 
The above nucleotide effects were specific for 
guanine nucleotides as indicated in table 1. Among 
the guanine nucleotides GTP and GDP are closely 
equipotent, while 3 ’ 5 ’ cGMP or GMP had no ef- 
fect. Among the analogs of GTP (GMPP(NH)P, 
GMPP(S)P and GMPP(CH2)P) GMPP(CH2)P 
was the least potent as observed in other systems 
[ 131 with the imido and sulfur analogs being close- 
ly equipotent (cf table 1). 
The guanine nucleotide effects observed with 
most agonists involve conversion of high affinity 
binding sites into low affinity binding sites with no 
apparent loss of the total number of receptors 
labelled by the agonist [7,8]. The present results, 
however, indicate an apparent loss of receptor sites 
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Fig. 1. (A) The equilibrium binding of ‘25 I-labelled NPY to membranes from rat cerebral cortex in the absence (0) or 
presence (0) of GTP (0.1 mM). (B) Scatchard plot of the data in A. 
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Fig.2. Inhibition of the equilibrium binding of lz51- 
labelled NPY (0.2 nM) by various concentrations of 
GTP and GMPP(NH)P. 
Table 1 
The influence of guanine and adenine nucleotides (0.1 
mM) on the equilibrium binding of ‘251-labelled NPY 
(0.2 nM) to receptors in membranes from rat cerebral 
cortex 
Nucleotide % Inhibition of 1251-labelled NPY 
(0.1 mM) binding= 
- 100 
GTP 63 f 3b 
GDP 69 * 8b 
GMP 92 + 2 
3’5’cGMP 96 + 5 
ATP 99 f 3 
AMPP(NH)P 110 rt 4 
3’5’cAMP 99 f 4 
GMPP(NH)P 65 + 5b 
GMPP(S)P 61 f 7b 
GMPP(CH2)P 82 f 4’ 
a Mean -t SD of quadruplicate determinations. 100% 
‘251-labelled NPY binding corresponds to 444 fmol/mg 
protein 
b Significantly different from control, p < 0.05 
’ Significantly different from control, p < 0.1 
for the agonist. To our knowledge there are two 
peptide hormone systems where similar results 
were obtained: (a) in the presence of GTP or 
GMPP(NH)P, almost 90% of the [iz51]iodo-N- 
Tyr-somatostatin binding disappears without a 
change in the binding affinity for the remaining 
sites [lo]; (b) in the presence of GMPP(NH)P, 
60% of substance P binding sites in membranes of 
rat salivary gland disappear without any change in 
the affinity for the remaining sites [9]. In addition, 
binding of the P-agonist fl-hydroxybenziliso- 
proterenol, shows both GTP-effects; reduction in 
the number of binding sites and change in affinity 
of agonist [14]. 
Plausible explanations for these effects are: (a) a 
GTP-caused desensitization; (b) strong negative 
cooperativity between agonist binding sites, induc- 
ed by a heterologous interaction with GTP; (c) the 
presence of two subpopulations of NPY receptors 
of which one is not coupled to any GTP binding 
protein and therefore unaffected by GTP binding, 
and another subpopulation which is coupled to 
GTP binding proteins and suffers such a large loss 
of affinity in the presence of GTP that NPY bind- 
ing to it using the limited concentration range of 
‘2SI-labelled NPY (fig.1) could not be detected. 
Lack of structural data on NPY receptors 
prevents distinction between the above alternatives 
for the time being. 
Guanine nucleotide-caused changes in the 
equilibrium binding of agonists are usually inter- 
preted as indicating that the agonist can either ac- 
tivate or inhibit the adenylate cyclase via a guanine 
nucleotide binding protein [6]. In the case of 
neuropeptide Y, we have so far not been able to 
demonstrate stimulation of cyclic AMP synthesis 
by NPY or inhibition of fi-agonists-induced cyclic 
AMP synthesis by NPY in tissue blocks from the 
rat cerebral cortex. 
Nevertheless, the experiments above suggest hat 
a guanine nucleotide binding protein (activatory or 
inhibitory) in the adenylate cyclase system [6] can 
be coupled to the NPY receptors and is capable of 
extensively influencing the binding of “‘1-NPY. 
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